Anticoagulation Management for Cerebral Venous Sinus Thrombosis

Acute‑Phase Anticoagulation

Initiate therapeutic low‑molecular‑weight heparin (LMWH) immediately in every patient with CSVT, even when intracranial hemorrhage is present, unless an absolute contraindication exists. 1
LMWH is the preferred agent over unfractionated heparin (UFH) for the first 5–10 days of treatment. 1
Subcutaneous LMWH should be started at the time of diagnosis. 1, 2
Intracranial hemorrhage that results from CSVT is not a contraindication to anticoagulation. 1, 2
Intravenous UFH may be used when sub‑cutaneous absorption is doubtful or when a subsequent thrombolytic approach is being considered. 3
The presence of hemorrhagic venous infarction should not delay anticoagulation; the hemorrhage is a consequence of venous congestion and will worsen without treatment. 1

Direct oral anticoagulants (DOACs) are now recommended over vitamin K antagonists (VKAs) for maintenance therapy after the acute phase, provided they are available and not contraindicated. 1
If DOACs cannot be used, warfarin targeting an INR of 2.0–3.0 remains an acceptable alternative. 1

Clinical scenario	Recommended duration of anticoagulation
CSVT provoked by transient risk factors (e.g., infection, pregnancy, oral contraceptives, minor head trauma)	3–6 months	[1, 2]
Unprovoked CSVT or mild thrombophilia	6–12 months, with reassessment at completion	[1, 2]
Severe thrombophilia, antiphospholipid syndrome, or recurrent CSVT	Lifelong therapy	[1]

Oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are preferred over LMWH for patients with cancer‑related CSVT. 4, 5
In the setting of gastrointestinal malignancy, apixaban or LMWH is favored because of a lower bleeding risk. 4, 5

Vitamin K antagonist therapy (target INR ≈ 2.5) is preferred to DOACs for CSVT associated with APS. 4, 5, 6
Initiation of VKA in APS requires overlapping parenteral anticoagulation until the therapeutic INR is achieved. 4, 5

Functional outcome should be evaluated at 90 days and again at 6 months after the index event. 1

Endovascular intervention—catheter‑directed thrombolysis with or without mechanical thrombectomy—should be considered when neurological status worsens despite adequate anticoagulation. 1, 2

Absolute contraindications include active intracranial bleeding unrelated to CSVT, recent neurosurgical procedures, severe thrombocytopenia (platelet count < 50 × 10⁹/L), and pre‑existing coagulopathy. 7
In patients with these contraindications, placement of an inferior vena cava (IVC) filter and/or endovascular therapy may be employed as alternative strategies. 1, 2